Explore

Trendline Trendline
Halia Therapeutics Expands Board with New Executive Chairman and Directors Amid Strategic Growth

Halia Therapeutics Expands Board with New Executive Chairman and Directors Amid Strategic Growth

Halia Therapeutics Expands Board with New Executive Chairman and Directors Amid Strategic Growth
Trendline Trendline
Halia Therapeutics Expands Board with New Executive Chairman and Directors to Drive Growth

Halia Therapeutics Expands Board with New Executive Chairman and Directors to Drive Growth

Halia Therapeutics Expands Board with New Executive Chairman and Directors to Drive Growth
Trendline Trendline
GenSight Biologics to Discuss Strategic Priorities at General Meeting

GenSight Biologics to Discuss Strategic Priorities at General Meeting

GenSight Biologics to Discuss Strategic Priorities at General Meeting
Trendline Trendline
Palatin Technologies to List on Nasdaq, Aiming for Enhanced Visibility and Liquidity

Palatin Technologies to List on Nasdaq, Aiming for Enhanced Visibility and Liquidity

Palatin Technologies to List on Nasdaq, Aiming for Enhanced Visibility and Liquidity
Trendline Trendline
Palatin Technologies to Transition Stock Listing to Nasdaq, Aiming for Greater Visibility

Palatin Technologies to Transition Stock Listing to Nasdaq, Aiming for Greater Visibility

Palatin Technologies to Transition Stock Listing to Nasdaq, Aiming for Greater Visibility
Trendline Trendline
Turn Therapeutics Appoints Former FDA Commissioner Dr. Stephen M. Hahn as Executive Clinical Lead

Turn Therapeutics Appoints Former FDA Commissioner Dr. Stephen M. Hahn as Executive Clinical Lead

Turn Therapeutics Appoints Former FDA Commissioner Dr. Stephen M. Hahn as Executive Clinical Lead
Trendline Trendline
Bronstein, Gewirtz Grossman, LLC Files Class Action Lawsuit Against Immutep Limited for Securities Violations

Bronstein, Gewirtz Grossman, LLC Files Class Action Lawsuit Against Immutep Limited for Securities Violations

Bronstein, Gewirtz Grossman, LLC Files Class Action Lawsuit Against Immutep Limited for Securities Violations
Trendline Trendline
ATB Therapeutics Appoints Mark Throsby as CEO to Lead Growth Phase

ATB Therapeutics Appoints Mark Throsby as CEO to Lead Growth Phase

ATB Therapeutics Appoints Mark Throsby as CEO to Lead Growth Phase
Trendline Trendline
Sanofi's Experimental Therapy for AATD Shows Promise in Phase 2 Trial

Sanofi's Experimental Therapy for AATD Shows Promise in Phase 2 Trial

Sanofi's Experimental Therapy for AATD Shows Promise in Phase 2 Trial
Trendline Trendline
Oligomerix Completes Phase 1a Study of Alzheimer's Drug OLX-07010, Showing Promise for Future Trials

Oligomerix Completes Phase 1a Study of Alzheimer's Drug OLX-07010, Showing Promise for Future Trials

Oligomerix Completes Phase 1a Study of Alzheimer's Drug OLX-07010, Showing Promise for Future Trials
Trendline Trendline
Enveric Biosciences Reports Q1 2026 Financial Results and Advances Lead Drug Candidate

Enveric Biosciences Reports Q1 2026 Financial Results and Advances Lead Drug Candidate

Enveric Biosciences Reports Q1 2026 Financial Results and Advances Lead Drug Candidate
Trendline Trendline
Faruqi Faruqi, LLP Alerts Immutep Investors of Securities Class Action Deadline

Faruqi Faruqi, LLP Alerts Immutep Investors of Securities Class Action Deadline

Faruqi Faruqi, LLP Alerts Immutep Investors of Securities Class Action Deadline